Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation

BACKGROUND: Agonists of 5‐hydroxytryptamine 4 receptor are potential agents for irritable bowel syndrome with predominant constipation (IBS‐C). However, only tegaserod has been approved for a very limited population in the US. AIM: To evaluate the efficacy and safety of minesapride in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamatani, Tatsuto, Fukudo, Shin, Nakada, Yosuke, Inada, Hiroshi, Kazumori, Kiyoyasu, Miwa, Hiroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383621/
https://www.ncbi.nlm.nih.gov/pubmed/32583907
http://dx.doi.org/10.1111/apt.15907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383621/
https://www.ncbi.nlm.nih.gov/pubmed/32583907
http://dx.doi.org/10.1111/apt.15907

Ejemplares similares